X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.

Press Room

Featured News

February 6, 2017       New study data reveal genomic testing with Oncotype DX helps reduce unnecessary chemotherapy treatment for breast cancer patients.
UK Press Image Breast Cancer Oncotype DX
Test could spare 6,000 breast cancer patients from chemotherapy - The Daily Mail

 


UK News

March 20, 2017   Genomic Health’s Oncotype DX® breast cancer test can significantly improve patient outcomes for node-positive patients, international studies reveal
     
February 6, 2017   NHS adoption of Oncotype DX® test leads to substantial reduction in unnecessary chemotherapy for UK breast cancer patients
     
December 12, 2016   New data demonstrate that Oncotype DX® can help guide treatment decisions before breast cancer surgery enabling more personalised care, including avoidance of full mastectomy
     
October 10, 2016   Large study shows older breast cancer patients have worse outcomes
     
June 20, 2016   Updated NICE quality standard recommends Oncotype DX® in early-stage breast cancer
     
June 6, 2016   Oncotype DX presentations at 2016 ASCO® annual meeting reinforce Genomic Health’s leadership in optimising breast cancer treatment
     
May 31, 2016   Innovative Oncotype DX test available in centres throughout West of Scotland Cancer Network to guide treatment decisions for early breast cancer patients
     
March 11, 2016   Five-year outcomes results from European ‘PlanB’ study show that breast cancer patients with low Oncotype DX Recurrence Score results can be spared chemotherapy despite having high-risk disease by traditional measures.
     
December 16, 2015   Major new study data demonstrates that the Oncotype DX test accurately predicts clinical breast cancer outcomes, bringing the total number of patients in prospective outcome studies to 50,000.
     
September 28, 2015   Large TAILORx outcomes study demonstrates 99% of patients with low Oncotype DX Recurrence Score results were breast cancer relapse-free following five years of hormone therapy alone.
     
February 5, 2015   As of April 1, 2015, the Oncotype DX test will be available, through an access scheme, as an option to help NHS clinicians in England decide whether to prescribe chemotherapy in people with early breast cancer.
     
September 25, 2013   NICE recommends Genomic Health’s Oncotype DX test to guide chemotherapy treatment decisions for qualified early-stage invasive breast cancer patients.

 

For global news please visit our U.S. website

Media Resources

For B-roll videos, images and infographics from Genomic Health, please visit our U.S.
Media Resources.

Images

For high-resolution images, email your request to media@genomichealth.com.
Oncotype SEQ
Laboratory
Laboratory Vial
Genomic Health Lab
Laboratory Slide
Genomic Health Sample
Scientist
Cancer Sample
Genomic Health Sample
Genomic Health Scientists
Genomic Health Scientists Working
Scientist in Lab
Genomic Health Cancer Samples Processed
Genomic Health Scientist in the Lab with Sample
Testing in the Lab
Processing Samples
Oncotype DX Samples
Genomic Health Oncotype DX
Oncotype DX in the Lab
Cancer Tissue
Samples Processed at Genomic Health
Tumor Tissue Processed